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1.Introduction 
Pulmonary embolism (PE) is a common disease with high morbidity and mortality, yet it is 
a disorder that is difficult to diagnose (Stein & Matta, 2010). 90% of the clinical PE originates 
from the proximal deep veins of the lower extremities. An ultrasonographic study involving 
patients diagnosed with pulmonary embolism detected thrombus in 29% of the deep veins 
(Anderson et al., 1991). Failure to demonstrate the presence of deep vein thrombosis (DVT) 
in many patients with pulmonary embolism results from the detachment of the emerging 
blood clot or the inability of ultrasonography to show minor clots (Anderson et al., 1991). 
Besides DVT, immobilization after fracture or surgical procedures, pregnancy, delivery and 
usage of estrogen containing oral contraceptives are the other predisposing factors for 
pulmonary emboli (Quinn et al., 1992). The predisposing factors were first described by 
Virchow in 1856 as consisting of three major phenomena (Table 1) (Anderson et al., 1991; 
Quinn et al.,1992): the “Virchow triad”, that is, the triad of the three factors that induce the 
process of vascular clotting: endothelial injury, hypercoagulability and lower extremity 
stasis (Carson et al., 1992). 
In 75% of pulmonary embolism cases, the acquired and/or hereditary factors that lead to 
one of these predisposing factors are detected; in half of the hereditary thrombophilia cases, 
an accompanying acquired risk factor is also present (White, 2003). Stasis in the lower 
extremities usually results from slow blood flow occurring in the patient groups with 
decreased mobility. In patients with endothelial injury, causes such as trauma and surgery 
trigger this process while hypercoagulation is a mechanism observed in cases of hereditary 
thrombophilia (White, 2003). Table 2 presents the acquired and hereditary risk factors.  
2. Genetic risk factors 
Among the hereditary risk factors leading to a predisposition to thrombosis, antithrombin 
deficiency was first shown to create predisposition to thrombosis in 1965, followed by the 
description of protein C deficiency in 1981 and protein S in 1984. These three deficiencies 
represent only 15% of hereditary thrombophilias. The description of the active protein C 
(APC) resistance by Dahlback et al in 1993 (Dahlback, 1995) and of the factor V Leiden 
mutation by Bertina in 1994 (Bertina, 1999) enabled elucidation of the etiology in 20% of 
patients with thrombosis and in 50% of families with thrombophilia. Similarly, 
hyperhomocysteinemia and a mutation in the prothrombin gene were shown to cause 
hereditary thrombophilia in 1994 and 1996, respectively (Makris et al., 1997). In patients 
with genetic thrombophilia, the predisposition to thrombotic and recurrent venous 
thromboembolism (VTE) in the early stages of life is increased.  
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Table 1.Virchow’s triad/ venous thromboembolism risk factors 
 
 
Genetic risk factors Acquired risk factors
Antithrombin III deficiency
Protein C deficiency 
Protein S deficiency  
Activated Protein C resistance and 
Factor V Leiden Mutation 
Factor II G20210A Mutation:  
Hyperhomocysteinemia 
Increase in Factor VIII Levels 
Congenital Dysfibrinogenemia 
Plasminogen deficiency  
Factor VII deficiency 
Factor XII deficiency  
Factor IX increase 
 
Advanced age
Obesity 
Long haul air travel  
Immobilization 
Major surgery 
Trauma 
Congestive cardiac failure / Myocardial 
infraction 
Smoking 
Stroke 
Malignity/ Chemotherapy 
Central venous catheter 
Pregnancy/puerperality 
The use of Oral contraceptives and hormone 
replacement 
Previous pulmonary emboli and deep vein 
thrombosis  
Antiphospholipid syndrome 
Chronic obstructive pulmonary disease (COPD)  
Medical Conditions requiring hospitalization 
Table 2. Risk factor for pulmonary embolism 
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2.1 Antithrombin III deficiency  
Antithrombin III (AT III) deficiency is among the first described thrombophilias. It is one of 
the most important natural protease inhibitors and a glycoprotein that is synthesized in the 
liver, which exhibits anticoagulant efficacy through inhibition of thrombin and the other 
serine proteases (factor IX a, X a, XI a, XIIa and kallikrein). Owing to these properties, it is 
accepted to be one of the most potent physiologic inhibitors of the fibrin formation. There 
are two types of antithrombin III deficiencies: type I involves reduction in the synthesis 
while type II involves functional inactivity. Type I AT III deficiency is characterized by both 
a functional and an immunological reduction in AT III. Type II AT deficiency involves 
variant AT III molecules (Thaler & Lechner, 1981). When the serum concentration of 
antithrombin III is mildly decreased, factor Xa, IXa, XIa and XIIa and thrombin cannot be 
inactivated, leading to thrombus formation. In addition to congenital deficiency, the 
antithrombin level is also decreased in cases of diffuse intravascular clotting, oral 
contraceptive (OC) use, and liver and kidney diseases. In antithrombin III deficiency, 
thrombotic events occur mostly in the mesenteric and lower extremity deep veins, leading to 
an increased predisposition to pulmonary embolism. A trial detected a rate of AT III 
deficiency at 1/600 in healthy individuals (Tait et al., 1994). In another trial, this figure was 
1.5% in patients diagnosed with VTE (Bauer& Rosenberg, 1991). 
2.2 Protein C deficiency 
Protein C (PC) is a glycoprotein synthesized in the liver. Its deficiency exhibits autosomal 
dominant or autosomal recessive inheritance. Protein C deficiency has two subtypes. Type I 
protein C deficiency: protein C antigen level is low due to genetic defect while the protein C 
activity is normal. Type II protein C deficiency involves the presence of an abnormal protein 
C molecule. Protein C antigen is normal while the protein C activity is low (Hoshi et al., 
2007). Protein C is activated after the thrombin binds to the endothelial receptors. Activated 
PC binds to the factor Va and factor VIIIa and inactivates these factors, thereby inhibiting 
the clot formation.  
In the general population, protein C deficiency prevalence is between 1/16000 and 36000. 
The fact that the protein C deficiency rate is 10% in patients with previous VTE below 40 
years of age and that it increases the VTE risk 6-fold, protein C level should be investigated 
in all young patients with previous VTE (Folsom et al., 2002). 
2.3 Protein S deficiency  
Protein S is a glycoprotein that is vitamin K-dependently synthesized, exhibits an autosomal 
dominant inheritance and activates protein C as a cofactor. Protein S exhibits anticoagulant 
efficacy through both the inactivation of factor Va and factor VIIIa by Protein C that is 
activated as a cofactor and directly through inhibition of the interaction of prothrombin with 
factor Va and Xa; therefore, protein S deficiency is considered a significant risk factor for 
thrombosis formation (Bertina, 1999). Protein S deficiency has three subtypes. Type I protein 
S deficiency involves a reduction in the total protein S antigen level. The free protein S 
antigen level and activity is low. Type II protein S deficiency involves the presence of a 
functionally abnormal protein S molecule. The total and free protein S antigens are normal 
but the protein S activity is decreased. Type III protein S deficiency involves a normal total 
protein S antigen but a decreased free protein S antigen level and activity (Dykes et al., 
2001). Protein S deficiency is observed at a rate of 0.03%-0.13 (Dykes et al., 2001) and 6% in 
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healthy individuals and families with thrombophilia (Bertina 1999). The trials performed 
demonstrated a 6 to 10-fold increased VTE risk in heterozygous Protein S gene carriers 
(Bauer& Rosenberg, 1991). As well as leading to thrombus formation in the deep (axillary, 
femoral etc), mesenteric, cerebral and superficial veins, it also causes PE and arterial 
thrombus formation. It is also one of the causes of recurrent VTE attacks. Pregnancy, OC or 
estrogen replacement use, nephritic syndrome, disseminated intravascular coagulation, HIV 
infection and liver diseases may also result in acquired protein S deficiency (Bauer& 
Rosenberg, 1991).  
2.4 Activated protein C resistance and factor V Leiden mutation 
In cases of activated partial thromboplastin time (aPTT) changes, an addition of activated 
Protein C to the plasma is expected to cause the prolongation of bleeding time. However, 
Dahlback et al detected no prolongation in some patients with VTE in 1993 (Dahlback, 1995); 
this phenomenon was described as the activated protein C resistance (APCR). Activated 
Protein C resistance is clearly associated with an increase in thrombosis incidence. The 
subsequent studies detected this phenotype in 20-50% of the patients with VTE (Dahlback, 
1995). In many cases of hereditary APCR, aG→A transition causes translocation of the 
amino acids (glutamine and arginine) at 506 location in the position 1691 nucleotide as a 
result of the activated function of the point mutation in factor V (site of cleavage for the 
activated PC in the factor V molecule). This point mutation was first described in 1994 and 
named as Factor V Leiden (FVL), FVR Q or FV: Q (Rosendaal et al., 1995). Factor V mutation 
notably increases the predisposition to VTE, causes hypercoagulability and neutralizes 
activated PC-mediated resistance. The risk of VTE is increased 3 to 8-fold in individuals 
heterozygous for factor Leiden mutation; as for homozygous individuals, the increase in the 
thrombotic risk is 50 to 100-fold (Rosendaal et al., 1995). The incidence of factor V Leiden 
carriers is 1-15% in the population (Rosendaal et al., 1995). Factor V Leiden is present in 10-
50% of the cases with VTE. Factor V Leiden abnormality results from a single mutation. In 
APCR without factor V Leiden mutation, the VTE risk is increased (Rosendaal et al., 1995).  
2.5 Factor II G20210A mutation  
A new genetic factor was discovered in the etiology of VTE in 1996. The G→A transition 
(Factor II G20210A) of the nucleotides at 20120 location in the region of the coagulation 
factor II gene not undergoing 3’-translation is associated with hyperprothrombinemia. G→A 
transition increased the prothrombin synthesis at the level of mRNA and protein synthesis. 
In heterozygous carriers of this mutation, the prothrombin level is increased 1.3-fold while it 
is increased 1.7-fold in homozygous carriers. The increase in the plasma prothrombin level 
results in a predisposition to thrombosis. This mutation was detected in 1-3% of the general 
population and 6-18% of the patients with VTE (Poort et al. 1996). Factor II G20210A 
diagnosis is only established by gene analysis. It is the second most common genetic 
abnormality, secondary to thrombophilia. In the case of factor II G20210A, there is no 
increase in the risk of VTE (Miles et al., 2001). 
2.6 Hyperhomocysteinemia 
It is the only hereditary cause of thrombophilia that has been proven to lead to arterial and 
venous thrombosis. Hyperthrombosis is believed to trigger the development of thrombosis 
via various mechanisms; there are in vitro studies showing that it affects the endothelial 
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cells by causing the formation of reactive oxygen forms, such as superoxide, hydrogen 
peroxide and hydroxyl radicals, it causes proliferative response by affecting the smooth 
muscle cells and increasing collagen production, it affects the clotting system by increasing 
tissue factor production in the monocytes, creating acquired APC resistance and increasing 
the synthesis of thromboxane in the platelets (Miletich et al., 1987). Hyperhomocysteinemia 
is an established risk factor for VTE and is usually associated with a 2 to 4-fold increased 
thrombotic risk. Plasma homocysteine concentration is affected by genetic and acquired 
factors and thus known as the mixed risk factor (Miletich et al., 1987). Vitamin B12, vitamin 
B6 and folate deficiency, advanced age, chronic renal failure and malnutrition involving 
anti-folic drug use represent acquired factors in hyperhomocysteinemia. Gene defects in two 
enzymes involved in the intracellular metabolism, methyltetrahydrofolate reductase 
(MTHFR) and cystathionine B-synthase (CBS) result in hyperhomocysteinemia and enzyme 
deficiency. Various mutations have been defined in methyltetrahydrofolate reductase and 
CBS to date; most are rare and lead to clinical outcomes in homozygous cases only. This 
condition is characterized by multiple neurological deficiency, physicomotor retardation, 
seizures, skeletal abnormalities, lens dislocation, premature arterial disease and VTE 
(Weisberg et al., 1999). Methyltetrahydrofolate reductase 677 C→T is associated with high-
prevalence polymorphism in the general population and reduced enzyme activity in 
homozygous cases. Methyltetrahydrofolate reductase 1298 A→C is not considered to be 
associated with hyperhomocysteinemia and not considered a thrombotic risk factor.  
However, MTHFR results in reduced enzyme activity and increased homocysteine levels in 
heterozygous cases of 677 C→T (Weisberg et al., 1999). 68-bp insertion in the cystathionine 
B-cynthase gene (844ins68) is a common mutation in various populations. This gene change 
has no effect on the risk of DVT or homocysteine levels. Hyperhomocysteinemia is not 
defined as a genetic abnormality for VTE but as an independent risk factor (Kluijtmans et 
al., 1997).  
2.7. Increase in factor VIII levels 
Factor VIII is an entity with a gene localized on the 10th chromosome, which activates the 
factor X by forming a complex with factor IXa and phospholipids in the coagulation cascade. 
The increase in factor VIII is included among the thrombotic risk factors since it further 
increases formation of thrombin from prothrombin by factor X activation (Schambeck et al., 
2004). The increased factor was detected in 3-9.4% of healthy individuals and in 11.3% of 
patients with VTE (Schambeck et al., 2004). A high FVIII level was reported to increase the 
VTE risk approximately 5-fold compared to individuals with a normal level (Schambeck et 
al., 2004). In addition, the factor VIII level was demonstrated to be an independent risk 
factor for VTE (Kraaijenhagen et al., 2000) (21) and to be correlated with the PE recurrence 
(Kyrle et al., 2000).  
2.8. Congenital dysfibrinogenemia 
The impairment in the formation of fibrin from fibrinogen secondary to the changes in the 
structure of fibrinogen is called dysfibrinogenemia. Dysfibrinogenemia is a dominant 
disease group characterized by qualitative abnormal fibrinogen formation. Various 
fibrinogen abnormalities are assessed within this group. Approximately 300 abnormal 
fibrinogen have been defined (Schorer et al., 1995). The most common structural defects are 
detected in fibrinopeptides and their sites of cleavage. Each dysfibrinogenemia affects 
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thrombin time and clotting in a different way. While some dysfibrinogenemias do not have 
the effect of bleeding or thrombosis, some may cause abnormal bleeding and even 
thrombosis (Schorer et al., 1995). 
2.9 Plasminogen deficiency  
Plasminogen (plg) plays an important role in intravascular and extravascular fibrinolysis, 
wound healing, cell migration, tissue remodeling, angiogenesis, and embryogenesis 
(Castellino & Ploplis, 2005).  
Plasminogen deficiency shows an autosomal dominant inheritance.  
Plasminogen deficiency is classified into two groups: one is type I deficiency characterized 
by the parallel reduction of both activity and antigen, and the other is dysplasminogenemia 
(type II) characterized by reduced activity with a normal antigen level (Schuster et al., 2001).  
Hypoplasminogenemia (type I plg deficiency): No significantly increased risk of deep 
venous thrombosis. In hypoplasminogenemia, or type I plg deficiency, the level of 
immunoreactive plg is reduced in parallel with its functional activity. The specific plg 
activity is normal. 
Some further case reports and family studies had originally suggested that heterozygous 
hypoplasminogenemia might be a risk factor for venous thrombosis (Leebeek et al., 1989). 
The relationship between hypoplasminogenemia and venous thrombosis has more recently 
been called into question, mainly based on two lines of evidence. Dysplasminogenemia 
(type II plg deficiency): in dysplasminogenemia, or type II plg deficiency, the level  
of immunoreactive plg is normal (or only slightly reduced), whereas the specific functional 
plg activity is markedly reduced because of abnormalities in the variant plg molecule 
(Robbins, 1990).  
2.10 Factor VII deficiency 
Inherited factor VII (FVII) deficiency is the most widespread of the rare inherited bleeding 
disorders, with an estimated prevalence of 1 in 400 000 Caucasians (Mariani et al., 2005). It is 
characterized by a wide heterogeneity as regards clinical, biological and genetic parameters. 
Clinical features are extremely variable, ranging from mild cutaneo-mucosal bleeding to lethal 
cerebral haemorrhages, and are poorly correlated with residual FVII coagulant activity 
(FVII:C). Moreover, several patients remain asymptomatic (Aynaoğlu et al., 2010), even under 
conditions of high haemorrhagic challenge. Notably, in some rare cases, patients have a 
history of arterial (Escoffre et al., 1995) or venous (Mariani & Bernardi, 2009) thromboses. The 
mechanisms accounting for the association of FVII deficiencies with thrombosis remain 
unclear. FVII deficiency is characterized by a wide heterogeneity, even amongst those patients 
presenting with rare thrombotic events. In a few case reports, thrombosis can occur in “usual” 
sites, such as the deep veins of the lower limbs or pulmonary embolism, or in atypical sites, 
such as the sinus veins (Lietz et al., 2005). The first series of FVII deficiency associated with 
thrombosis included seven cases of venous thrombosis, localized primarily in typical sites 
(lower limbs and pulmonary embolism) (Mariani et al., 2005). 
2.11 Factor XII deficiency  
Severe FXII deficiency (FXII activity <1%) shows an autosomal recessive inheritance and 
patients are detected to have a prolonged aPTZ time. Despite this prolongation in the active 
partial thromboplastin time, patients do not have bleeding diathesis. In contrast, these 
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patients develop VTE and myocardial infarction. While the incidence of thrombosis 
secondary to factor XII deficiency was not well-established, it was reported to be 8% 
approximately (Goodnough et al., 1983).  
2.12 Factor IX increase 
Factor IX plays a key role in hemostasis; it is a vitamin K–dependent glycoprotein, which is 
activated through the intrinsic pathway as well as the extrinsic pathway (B. Furie & BC. 
Furie, 1988). Factor IX, when activated by factor XIa or factor VIIa-tissue factor, converts 
factor X into Xa and this eventually leads to the formation of a fibrin clot. This conversion is 
accelerated by the presence of the nonenzymatic cofactor factor VIIIa, calcium ions, and a 
phospholipid membrane (van Dieijen et al., 1981). In healthy individuals, factor IX activity 
and antigen levels vary between 50% and 150% of that in pooled normal plasma (B. Furie & 
BC. Furie, 1988; van Dieijen et al., 1981). Individuals who have high levels of factor IX (>129 
U/dL) have a more than 2-fold increased risk of developing a first DVT compared with 
individuals having low levels of factor IX. The risk of thrombosis increased with increasing 
plasma levels of factor IX (dose response). At factor IX levels of more than 125 U/dL, an 
increase of the risk can already be observed compared with the reference category (factor IX 
levels ≤100 U/dL). Individuals with a factor IX level over 150 U/dL have a more than 3-fold 
increase in the risk of thrombosis when compared with the reference category.  
3. Acquired risk factors 
3.1 Advanced age 
The VTE incidence increases linearly with the age. Above 50 years of age, the PE incidence 
was detected to be higher in women. This increase is also associated with other 
comorbidities (cancer, myocardial infarction) that increase with age (Stein et al., 1999). 
3.2 Obesity 
The risk of PE by obesity is correlated with the body mass index. While the relative risk of 
pulmonary embolism is 1.7 for those with a body mass index of 25-28.9 kg/m², it is 
increased 3.2-fold for those with a BMI ≥29 (Goldhaber et al., 1997). Obesity is correlated 
with VTE, particularly in women. It was reported to be an independent risk factor in women 
with a body mass index ≥ 29. However, there are controversial study results on this subject 
(Goldhaber et al., 1997). 
3.3 Long haul air travel  
Air travel is a risk factor for PE. In a trial by Lapostolle et al, severe pulmonary embolism 
was detected in 56 of 135.29 million passengers from 14 countries. The assessment of the 
results revealed a rate of 1.5 in one million cases in those flying more than 5000 km and a 
rate of 4.8 in one million cases in those flying more than 10000 km, leading to the reported 
result that PE risk was correlated with flight distance. Conditions that lead to 
hemoconcentration during air travel, such as dehydration, lower oxygen pressure and foot 
swelling are believed to induce venous stasis (Lapostolle et al., 2001). 
3.4 Immobilization 
Immobility is a condition that is most commonly observed in PE, which may concomitantly 
exist with other risk factors (Stein et al., 1999). Long-term absence of mobilization results in 
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a weakening of the muscles that provide an upward flow of the blood in the leg veins. The 
blood accumulates backwards; thus, among the activated platelets and clotting factors, 
thrombin in particular accumulates locally, leading to the formation of thrombus. Even if for 
a short time, for example one week, in the postoperative period, immobilization increases 
the risk of VTE (Stein et al., 1999).  
3.5 Major surgery 
Surgical intervention is one of the most significant acquired risk factors that cause PE. The 
decreased mobility during the operation, hypercoagulation secondary to local trauma and 
endothelial injury, the prothrombotic process that may be caused by the general anesthesia 
administered increase the risk of PE (Rosendaal, 1999). The presence of operation history 
within a 45-90 day period increases the risk of thromboembolism 6 to 22-fold (Rosendaal, 
1999); 25% of these emboli occur after discharge from the hospital (Huber et al., 1992). 
Surgeries of the hip, knees, and the abdominopelvic region represent the most risky 
operations for venous thromboembolism development (Huber et al., 1992). 
3.6 Trauma 
Trauma is also a risk factor for PE development; the localization of the trauma is very 
important with respect to venous thrombus development (Geerts et al., 1996). VTE occurs in 
50% of chest or abdomen traumas, 54% of head traumas and 62% of spinal cord injuries, and 
69% of lower extremity orthopedic traumas (Geerts et al., 1996). The incidence of venous 
thromboembolism increases proportionally with time after the traumatic event. While the 
rate of PE confirmed by autopsy was 3.3% in those who survived less than 24 hours after 
trauma, this rate was 5.5% in those who survived up to seven days. PE was reported at a 
rate of 18.6% in individuals who survived longer (Geerts et al., 1996). Patients over 45, a 
requirement of more than three days bed rest, a previous history of VTE, fractures of the 
lower extremity, pelvis, spine, the development of coma and plegia, a requirement for blood 
transfusion and surgery further increase the risk of DVT and PE, therefore, effective and safe 
prophylactic anticoagulant treatment is recommended in traumatic patients unless 
contraindicated (Shackford et al., 1990).  
3.7 Congestive cardiac failure/myocardial infraction 
The presence of congestive cardiac failure or arrhythmia underlying heart disease further 
increases the risk of PE. In cardiac failure, the risk of mortality from PE is increased due to 
decreased cardiopulmonary reserve (Anderson & Spencer, 2003). The increase of factor VIII, 
fibrinogen and fibrinolysis in the acute phase following acute myocardial infarction leads to 
PE (Anderson & Spencer, 2003). Nearly all of the PEs occurring in acute myocardial 
infarction result from deep vein thrombosis in the lower extremity. Very rarely, they result 
from mural thrombi occurring in the infraction site in the right ventricle (Anderson & 
Spencer, 2003). 
3.8 Smoking 
Smoking may increase the risk of VTE through a number of mechanisms:  
1. Smoking is a well established, potent risk factor for a number of diseases, including 
cancer and cardiovascular diseases (stroke and coronary heart diseases); these, in turn, 
are associated with an increased risk of VTE. Therefore, smoking might be associated 
with the risk of provoked VTE.  
www.intechopen.com
 
Risk Factor for Pulmonary Embolism 
 
9 
2. Smoking is associated with a higher plasma concentration of fibrinogen (Yanbaeva et 
al., 2007; Lee & Lip, 2003).  
3. Smoking is associated with reduced fibrinolysis (Lee & Lip, 2003; Yarnell et al., 2000).  
4. Smoking is associated with inflammation (Yanbaeva et al., 2007; Yarnell et al., 2000). 
5. Smoking increases the viscosity of the blood (Yanbaeva et al., 2007; Lee & Lip, 2003).  
3.9 Stroke 
Most patients with acute ischemic stroke or intracranial hemorrhage survive the initial 
event. Early in-hospital mortality has been attributed not only to swelling of the brain and 
enlargement of hematoma but also to aspiration pneumonitis, sepsis, and severe heart 
disease (Brandstater et al., 1992). Pulmonary embolism after a stroke has received some 
attention, but the incidence is considered small. The incidence of clinical PE reported in the 
absence of heparin prophylaxis varies considerably, depending on the methodology of the 
studies. In the International Stroke Trial, the incidence was 0.8% at 2 weeks (International 
Stroke Trial Collaborative Group [ISTCG], 1997). Similarly, in a retrospective study of 607 
patients who had acute stroke, PE was reported in 1% during the period of hospitalization 
(Davenport et al., 1996). However, prospective studies that focused specifically on venous 
thromboembolic complications reported incidences of clinically apparent PE of 10% to 13% 
(excluding pulmonary emboli identified in autopsy that were asymptomatic during life) 
(Warlow et al., 1972).  In a retrospective study of 363 patients who did not receive heparin 
prophylaxis and entered a rehabilitation unit four weeks after stroke, 4% developed PE 
(confirmed by VQ scanning) on average 11 days after entering the unit (Subbarao & Smith, 
1984). Only one small study has prospectively screened for PE by using VQ scintigraphy. 
Dickmann et al (Dickmann et al., 1988) studied a group of 23 patients 10 days after 
hemorrhagic stroke and found evidence of PE in 39%, though the proportion with 
symptoms was not stated. Autopsy studies show that half of the patients who die in hospital 
after the first 48 hours post stroke have evidence of PE, (McCarthy & Turner, 1986) which 
suggests that pulmonary emboli are often subclinical and/or unrecognized after stroke. 
3.10 Malignity/chemotherapy 
Cancer patients have a higher risk of complications and recurrence compared to patients 
without cancer. This risk is more marked especially in the pancreas, pulmonary disease, 
gastrointestinal system and mucinous carcinoma patients (Er & Zacharski 2006). Different 
mechanisms were proposed for the development of thrombotic predisposition in cancer 
patients. Development of procoagulant activity by the tumor products, coagulatory 
macrophage activation, endothelial cell injury and platelet activation secondary to 
interaction with the tumor cells are among these mechanisms. Some malignities (pancreas, 
colon, lungs and promyelocytic leukemias) systemically result in activation of the clotting 
system, leading to thrombotic complications. In cancer patients, the serum concentrations of 
the clotting factors, such as factors V, VIII, VII and fibrinogen are increased. Again, in these 
patients, local or systemic coagulation may occur secondary to vascular wall injury and 
factor X is activated (Falanga & Zacharski, 2005). The chemotherapeutical agents used for 
DVT after chemotherapy are significantly involved in this process due to the endothelial 
injury occurring in the vein to which these agents are administered (Nightingale et al., 1997). 
3.11 Central venous catheter 
Jugular, subclavian and femoral venous catheters lead to vascular injury and represent a 
focus for thrombus formation. Although less common, these patients may develop 
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symptomatic PE caused by the catheter-associated upper extremity thrombi (Haire & 
Lieberman 1992). In approximately 10-20% of the cases with pulmonary emboli, the emboli 
results from the thrombus in the site of the superior vena cava. Recently, upper extremity 
venous thrombus has been commonly known to occur as a result of invasive diagnostic and 
therapeutical procedures (intravascular catheter and intravenous chemotherapeutical 
agents) (Haire & Lieberman 1992).  
3.12 Pregnancy/puerperality 
Compared to the age-matched individuals, the risk of VTE is 5-fold higher in pregnant 
women. While 75% of the deep vein thrombi occur in the pre-delivery period, 66% of the 
PEs develop after the delivery. The risk is 20-fold higher in the postpartum period relative to 
the antepartum period (Kovacevich et al., 2000; Greer, 2003). Venous stasis secondary to 
dilated uterus in pregnancy, hormonal venous atonia, increased levels of thrombin and 
various clotting factors (fibrinopeptide A), increased platelet activation, decreased acquired 
protein S, antithrombin deficiency, the decreased APC response due to factor VIII increase 
are the risk factors. There are no trials using objective diagnostic techniques to show that 
cesarean section involves an additional thrombotic risk relative to normal delivery. The risk 
of a thrombotic event is higher in patients who are on mandatory bed rest due to premature 
action or preterm premature membrane rupture (Kovacevich et al., 2000). Since oral 
anticoagulation is risky for the fetus, low-molecule weight heparin treatment with a lower 
osteoporosis risk relative to the conventional heparin that will be maintained at least until 
puerperality appears to be an appropriate choice (Greer, 2003). 
3.13 The use of oral contraceptives and hormone replacement 
Oral contraceptive (OC) use was shown to increase the risk of PE approximately 3-7-fold. 
Oral contraceptives result in PE by increasing the levels of coagulation factors, such as 
prothrombin, factor VII, factor VIII, factor X and fibrinogen, and decreasing the levels of the 
coagulation factors, such as antithrombin III and protein S (Spitzer et al., 1996). Compared to 
the persons who are not on oral contraceptives, the risk was detected to be 3.4 for low-
estrogen levonorgestrel and 7.3 and 10.2 for the 3rd generation progesterone desogestrel and 
gestodene (World Health organization [WHO], 1995). Third generation OC use increases the 
VTE risk particularly in Factor V Leiden mutation carriers and those with a positive familial 
history (Bloemenkamp et al., 1995). In women, hormone replacement therapy used in the 
postmenopausal period is reported to be a risk factor for PE (Cushman et al., 2004). This risk 
is higher in patients with coronary artery disease. The risk is higher at the start of treatment 
and disappears upon discontinuation of the hormone replacement therapy. The mechanism 
involved in the increase of thrombosis by estrogen alone or in combination with 
progesterone is not known. However, recent trials report that OCs cause a reduction in the 
sensitivity to activated protein C irrespective of the type of drug used and that this 
reduction is higher with 3rd generation monophasic OCs relative to 2nd generation drugs 
(Rosing et al., 1997). 
3.14 Previous pulmonary emboli and deep vein thrombosis  
Hospitalized patients with a history of pulmonary emboli have a significant risk of 
recurrence. More than 50% of patients with a history of venous thromboembolism 
undergoing surgery develop postoperative DVT if no prophylaxis is administered. The rate 
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of recurrence within 5 years after the first DVT is 21.5% (Hansson et al., 2000). Jeffrey et al 
(Jeffrey et al., 1992) detected the PE recurrence as 8.3% and reported that recurrence 
occurred mostly within the first week of treatment. In addition, mortality was 45% in these 
patients.  
3.15 Antiphospholipid syndrome 
Antiphospholipid syndrome (APS) characterized by arterial and venous thrombosis 
predisposition, repeated miscarriage and the presence of antiphospholipid antibodies is one 
of the leading causes of acquired thrombophilia. While the pathogenesis of the syndrome is 
not elucidated clearly, the negatively charged phospholipids and the phospholipid 
antibodies developing against the phospholipid protein complexes (lupus anticoagulant-LA 
and anticardiolipin antibodies-AKLA) are believed to be responsible for clinical 
manifestations. In AFS, the most important factor affecting mortality and morbidity is 
thromboembolic complications. Thromboses can both involve the arterial and the venous 
system and may be observed in each tissue and organ. The recurring tendency of the 
thromboses and the high risk of consecutive thrombotic complications involving the same 
system (for example, recurrent arterial thrombosis in a case with previous arterial 
thrombosis) are interesting. Approximately 2/3 of the cases develop venous 
thromboembolism and 1/3 develop arterial thrombosis. In venous thrombosis, DVT and PE 
rank first while ischemic cerebral attack ranks first in arterial thrombosis followed by 
myocardial infarction and digital thromboses. Thrombosis in abnormal regions is common 
in antiphospholipid syndrome (thrombosis in upper extremity veins, intra abdominal veins 
and the veins inside the head) (Hanly, 2003). 
3.16 Chronic Obstructive Pulmonary Disease (COPD)  
COPD is a major health burden worldwide. It is the fourth-leading cause of mortality, 
accounting for > 3 million deaths annually; and by 2020, COPD will be the third-leading 
cause of death, trailing only ischemic heart disease and stroke. Most COPD-related deaths 
occur during periods of exacerbation (Sapey & Stockley, 2006). Previous studies (Sidney et 
al., 2005) estimate that 50 to 70% of all COPD exacerbations are precipitated by an infectious 
process, while 10% are due to environmental pollution. Up to 30% of exacerbations are 
caused by an unknown etiology Sapey & Stockley, 2006). Exacerbations are characterized by 
increase in cough and dyspnea. A study (Sidney et al., 2005) suggests that patients with 
COPD have approximately twice the risk of PE and other venous thromboembolic events 
(VTE) than those without COPD. Since thromboembolic events can lead to cough and 
dyspnea (just like infectious events), PE may be another common cause of COPD 
exacerbations (Tapson, 2008). However, dissimilar to infectious etiologies, which are 
effectively treated by antimicrobials and systemic corticosteroids, thromboembolic diseases 
require anticoagulant therapy and significant delays in treatment are associated with poor 
outcomes (Hull et al., 1997). Owing to multiple perfusion and ventilation abnormalities 
frequently observed in COPD lungs (even in the absence of VTE), noninvasive diagnosis of 
PE using imaging modalities was a significant challenge until quite recently. With the 
advent of contrast-enhanced (multidetector) CT, it is now possible to reliably diagnose PE in 
COPD subjects with minimal discomfort or risk to the patients. The primary purpose of this 
review was to determine the reported prevalence of PE in patients with COPD who required 
hospitalization for their disease. 
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3.17 Medical conditions requiring hospitalization 
The incidence of thromboembolic diseases in inpatients is reported to be different 
depending on the type of disease. While the risk is reported to be 3% in patients without risk 
factors, it is reported to be 50% in patients with previous VTE. Massive PEs account for 4-8% 
of inpatient mortality (Rubinstein et al., 1988). The VTE risk is higher in patients with 
neurological and cardiac diseases during hospitalization compared to other patient groups 
(Nicolaides et al., 2001). There are certain diseases that have been proven to increase the risk 
of venous thromboembolism complications; these include SLE, inflammatory intestinal 
diseases, nephritic syndrome, paroxysmal nocturnal hemoglobinuria, myeloproliferative 
diseases, Behcet’s disease, Cushing syndrome and sickle cell syndrome. The number of DVT 
cases is larger in these diseases relative to the general population.  
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